News | July 21, 2021
Granules clears US FDA audit
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The company has already embarked upon significant expansion in Turkey
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Subscribe To Our Newsletter & Stay Updated
